Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
10.4068/cmj.2016.52.3.159
- Author:
Sheng Min WANG
1
;
Changsu HAN
;
Soo Jung LEE
;
Tae Youn JUN
;
Ashwin A PATKAR
;
Prakash S MASAND
;
Chi Un PAE
Author Information
1. Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea. pae@catholic.ac.kr
- Publication Type:Clinical Trial
- Keywords:
Antidepressive Agents;
Depressive Disorder;
Clinical Trial;
Antipsychotic Agents;
Depressive Disorder, Treatment-Resistant
- MeSH:
Antidepressive Agents;
Antipsychotic Agents;
Depressive Disorder;
Depressive Disorder, Major;
Depressive Disorder, Treatment-Resistant;
Humans;
United States Food and Drug Administration
- From:Chonnam Medical Journal
2016;52(3):159-172
- CountryRepublic of Korea
- Language:English
-
Abstract:
Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.
